Dr. Kent William Mouw, MD, PhD

Dr. Mouw practices at Brigham and Women's Hospital in Boston, Massachusetts, part of Mass General Brigham.

Dr. Mouw's NPI, 1407176084, was assigned on June 7, 2010. Dr. Mouw graduated from University of Chicago, Pritzker School of Medicine in 2010. Dr. Mouw holds Massachusetts license 253571.

Dr. Mouw's primary practice is Brigham and Women's Hospital, at 75 Francis Street, Boston, MA 02115 in Suffolk County. The practice phone is (617) 732-5500.

Dr. Mouw's primary practice is Brigham and Women's Hospital in Boston, Massachusetts, part of Mass General Brigham. Dr. Mouw is also affiliated with Dana-Farber Cancer Institute. The medical group on file is Massachusetts General Physicians Organization (MGPO). Dmand AI also links Dr. Mouw to 3 more medical groups and 1 hospital outpatient department, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mouw practices, 3 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Mouw's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Mouw is licensed in Massachusetts.

CMS data shows 575 Medicare services from Dr. Mouw across 8 procedure codes in 2024, for 88 Medicare patients. Medicare paid $46,716 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 88 Medicare patients who saw Dr. Mouw in 2024. The largest group is 65 to 74, with 40 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 1.51, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mouw's median patient age at 73, with 20% women.

In 2024, Dr. Mouw wrote 28 Medicare Part D claims for 11 patients. 100% of them were for generic drugs. CMS names the drug for 25 of them, across 1 drug with 11 or more claims each, at $689 in total drug cost. In 2023, CMS named 32 claims across 1 drug.

Dr. Mouw accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mouw as offering telehealth.

Dmand AI links 113 papers to Dr. Mouw, published from 2012 to 2025. 2018 was the busiest year, with 13. The most frequent topics are Prostatic Neoplasms, Urinary Bladder Neoplasms and DNA Repair. Dr. Mouw has published most often in Int J Radiat Oncol Biol Phys. Dr. Mouw's most frequent co-authors are Paul L. Nguyen, MD, Neil E. Martin, MD and Brandon Mahal, MD.

Dmand AI links Dr. Mouw to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Urinary Bladder Neoplasms and Urinary Bladder Diseases.

CMS Open Payments shows 26 general payments to Dr. Mouw from 9 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 70% of the total. Urogen Pharma, Inc. paid the most, $6,400.

Dr. Mouw graduated from University of Chicago, Pritzker School of Medicine in 2010.